Dynavax Technologies Corporation $DVAX Stock Position Lowered by Principal Financial Group Inc.
Principal Financial Group Inc. reduced its stake in Dynavax Technologies Corporation by 12.9% in the third quarter, selling over 70,000 shares. This comes amidst insider selling by COO David F. Novack, who decreased his holding by over 64%. Despite institutional ownership at nearly 97%, the biopharmaceutical company holds a consensus "Hold" rating from Wall Street with a target price of $24.33, while currently trading at $15.50 with a negative PE ratio.
Wall Street Zen Upgrades Dynavax Technologies (NASDAQ:DVAX) to "Strong-Buy"
Wall Street Zen has upgraded Dynavax Technologies (NASDAQ:DVAX) to a "strong-buy" rating, despite other analysts generally maintaining a "Hold" consensus with a $24.33 price target. The article notes recent insider selling by COO David F. Novack, who sold a significant portion of his holdings, while institutional ownership remains high. Dynavax, a biopharmaceutical company known for its HEPLISAV-B vaccine, has shown strong liquidity metrics and a market capitalization of $1.82 billion.
Sanofi Completes $2.2-Bn Acquisition of Dynavax
Sanofi has finalized its $2.2 billion acquisition of Dynavax Technologies, a vaccines company. The acquisition brings Dynavax's adult hepatitis B vaccine, Heplisav-B, known for its two-dose regimen, into Sanofi's portfolio, along with a shingles vaccine candidate and other pipeline projects. This move strengthens Sanofi's position in the vaccine market.
Dynavax Technologies Announced Transfer or Voluntary Withdrawal of Listing
Dynavax Technologies Corporation (DVAX) announced that it requested Nasdaq to halt trading and delist its shares effective February 10, 2026, following the closing of its merger. The company also plans to file forms to remove its shares from listing and registration and to terminate its reporting obligations under the Exchange Act. This action was taken after consummating the merger.
Dynavax Technologies Signs Multiple Material Agreements
Dynavax Technologies (DVAX) has signed two First Supplemental Indentures with U.S. Bank Trust Company, amending its 2.50% Convertible Senior Notes due 2026 and 2.00% Convertible Senior Notes due 2030. These amendments, effective February 10, 2026, convert the settlement mechanism to cash-only based on a $15.50 offer price following a merger. This change reflects the merger being considered a fundamental change and make-whole event as per the indentures.
Dynavax Technologies Announces Board and Officer Changes Following Merger
Dynavax Technologies Corp (DVAX) announced significant board and executive team changes on February 10, 2026, following a merger. François-Xavier Dazogbo has been appointed as the sole director and officer, with several other individuals stepping into key executive roles. The changes include both resignations and appointments, effective immediately after the merger.
Assessing Dynavax Technologies (DVAX) Valuation After Recent Share Price Momentum And Ongoing Pipeline Investment
Dynavax Technologies (DVAX) has seen recent share price momentum with a 54.13% return in the last 90 days, despite reporting a net loss. The company's valuation is driven by its vaccine portfolio, including HEPLISAV B, and its development pipeline for shingles, pandemic influenza, and Lyme disease vaccines. Analysts currently assess DVAX as undervalued at $15.49, with a fair value of $19.25, contingent on revenue growth and pipeline success.
Sanofi Buyout Of Dynavax Recasts Adult Vaccine Growth For Shareholders
Sanofi has agreed to acquire Dynavax Technologies in a multi-billion dollar deal, aiming to expand its adult vaccine portfolio with Dynavax's hepatitis B and experimental shingles vaccines. This acquisition provides immediate cash value to Dynavax shareholders, shifting the focus from long-term growth potential to the agreed-upon sale price and integrating Dynavax's assets into a larger global platform. Investors should monitor closing milestones, potential competing bids, and how the underlying vaccine assets are valued within Sanofi's broader strategy.
(DVAX) Movement as an Input in Quant Signal Sets
This article analyzes Dynavax Technologies Corporation (NASDAQ: DVAX) using AI models, indicating a neutral sentiment across all time horizons. It provides three distinct institutional trading strategies: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy. The analysis suggests a wait-and-see approach due to no clear price positioning signal and elevated downside risk.
AlphaQuest LLC Boosts Stock Position in Dynavax Technologies Corporation $DVAX
AlphaQuest LLC significantly increased its stake in Dynavax Technologies Corporation by 109.9% in Q3, now owning 173,140 shares. This move contrasts with COO David F. Novack's sale of 114,000 shares. Dynavax reported strong Q3 earnings, beating analyst expectations, and has a MarketBeat consensus rating of "Hold" with a target price of $24.33.
Sanofi (DVAX) tender offer wins antitrust clearance as shareholders sue
Sanofi's indirect subsidiary, Samba Merger Sub, has amended its cash tender offer for Dynavax Technologies shares at $15.50 per share. The offer has received key regulatory clearances, with the U.S. Hart-Scott-Rodino waiting period expiring and German merger control clearance obtained. However, the transaction faces multiple shareholder lawsuits and demands challenging disclosures and seeking to delay or unwind the deal, which Dynavax intends to vigorously defend.
Sanofi to Acquire Dynavax Technologies in $2.2 Billion Deal
Sanofi has announced an agreement to acquire Dynavax Technologies Corporation, a publicly traded vaccines company, in a deal valued at $2.2 billion. Weil Gotshal & Manges advised Sanofi on the acquisition, while Cooley advised Dynavax Technologies. Further details are restricted to members of the Global Legal Chronicle.
Liquidity Mapping Around (DVAX) Price Events
This article provides a liquidity mapping analysis for Dynavax Technologies Corporation (NASDAQ: DVAX), identifying a neutral sentiment across all time horizons, suggesting a wait-and-see approach. It highlights elevated downside risk due to a lack of long-term support signals and outlines three AI-generated trading strategies tailored for different risk profiles: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy. The analysis includes specific entry zones, targets, and stop losses for each strategy, along with multi-timeframe signal analysis.
Dynavax Technologies (NASDAQ:DVAX) COO Sells $1,782,960.00 in Stock
Dynavax Technologies COO David Novack sold 114,000 shares of the company's stock for $1,782,960.00, reducing his stake by over 64%. The biopharmaceutical company reported strong quarterly earnings, beating analyst estimates, and has a current market capitalization of $1.84 billion. Despite mixed analyst ratings, institutional investors hold a significant portion of the company's shares.
Dynavax Technologies (NASDAQ:DVAX) Stock Passes Above 200 Day Moving Average - Time to Sell?
Dynavax Technologies (NASDAQ:DVAX) shares recently crossed above their 200-day moving average, trading at $15.63 with significant volume. Despite beating Q3 earnings estimates, the company still faces a negative net margin, and its COO recently sold a substantial number of shares. Analyst ratings are mixed, with a consensus "Hold" but individual recommendations spanning from "Strong-Buy" to "Sell."
Dynavax president Novack sells $1.78m in shares
Dynavax President and COO David F. Novack sold 114,000 shares of common stock for $1.78 million, while simultaneously exercising options to acquire the same number of shares. This transaction occurred as the company's stock trades near its 52-week high and shows significant growth. The company, though currently unprofitable, is expected to achieve profitability this fiscal year, and Sanofi has agreed to acquire Dynavax for $2.2 billion, offering a substantial premium.
Jim Cramer Highlights Sanofi’s Bid for Dynavax
Jim Cramer highlighted Sanofi's acquisition of Dynavax Technologies Corporation (NASDAQ: DVAX), valuing it at nearly $2.2 billion. The deal involves a cash tender offer of $15.50 per share for the biopharmaceutical company known for its hepatitis B vaccine. Cramer congratulated a caller who had bought Dynavax shares three years prior for $12, acknowledging the successful outcome of the investment due to the acquisition.
Dynavax adds two new directors, announces board retirements
Dynavax Technologies announced the appointment of two new independent directors, Cynthia Butitta and Richard Eisenstadt, to its board. Concurrently, the company announced the retirements of Shelley Farriss and Charles Ling, effective December 31, 2024. These changes aim to enhance the board's expertise as Dynavax continues to grow.
Dynavax Technologies stock hits 52-week high at $15.68 By Investing.com
Dynavax Technologies Corporation's stock reached a new 52-week high of $15.68, reflecting a 25.32% increase over the past year and a 45.65% return in the last six months. The company's strong financial position, with a market capitalization of $1.78 billion and a current ratio of 7.62, along with recent impressive Q3 2025 earnings and a $2.2 billion acquisition offer from Sanofi, contribute to this market confidence despite the stock being in overbought territory.
Dynavax Technologies stock hits 52-week high at $15.68 By Investing.com
Dynavax Technologies Corporation's stock has reached a new 52-week high of $15.68, reflecting a 25.32% increase over the past year and a 45.65% return over the last six months. With a strong financial position, including a market capitalization of $1.78 billion and a current ratio of 7.62, the company recently reported strong Q3 2025 earnings and is set to be acquired by Sanofi for $2.2 billion. InvestingPro analysis, however, suggests the stock is currently in overbought territory.
Dynavax Technologies stock hits 52-week high at $15.68
Dynavax Technologies (DVAX) stock has reached a new 52-week high of $15.68, reflecting significant investor confidence with a 25.32% increase over the past year and a 45.65% return in the last six months. The company's strong financial position, including a market capitalization of $1.78 billion and a current ratio of 7.62, supports its ongoing success in vaccine development. Recent news also highlights strong Q3 2025 earnings and an agreement for Sanofi to acquire Dynavax for $2.2 billion, representing a substantial premium.
Dynavax Technologies (NASDAQ:DVAX) Sets New 12-Month High - Still a Buy?
Dynavax Technologies (NASDAQ:DVAX) recently hit a new 52-week high of $15.71, though analyst ratings are split with a consensus "Hold" and a target price of $24.33. The biopharmaceutical company reported an EPS beat and strong liquidity but maintains negative net margins and P/E. Institutional ownership is high at 96.96%, despite a recent insider sale by the COO.
Dynavax gains on disclosure another bidder interested after deal announced (DVAX:NASDAQ)
Dynavax (DVAX) shares rose 1.9% following the disclosure of another interested bidder after the company had already agreed to be acquired by Sanofi (SNY) last month. This development caused Dynavax shares to trade above the initial $15.50 per share deal agreed upon with Sanofi.
Dynavax Technologies stock hits 52-week high at $15.68 By Investing.com
Dynavax Technologies (DVAX) stock has reached a new 52-week high of $15.68, reflecting a 25.32% increase over the past year and a 45.65% return in the last six months. The company, known for vaccine development, boasts a market capitalization of $1.78 billion and a strong current ratio of 7.62. Recent news includes strong Q3 2025 earnings and Sanofi's agreement to acquire Dynavax for $2.2 billion, a 39% premium over its closing share price on December 23, 2025.
Dynavax Technologies Corporation (NASDAQ:DVAX) Surges 42% Yet Its Low P/S Is No Reason For Excitement
Dynavax Technologies Corporation (NASDAQ:DVAX) has seen a significant 42% surge in its shares over the last month, contributing to a 20% gain year-to-date. Despite this momentum, the company's low price-to-sales (P/S) ratio of 5.5x, compared to an industry average of 11.5x, indicates that investors are not enthusiastic about its future growth prospects. Analysts forecast Dynavax's revenue to grow by 15% annually, significantly trailing the biotech industry's projected 123% annual expansion, which explains the depressed P/S ratio.
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Dynavax Technologies Corporation (NASDAQ: DVAX)
Monteverde & Associates PC, a prominent M&A class action firm, is investigating Dynavax Technologies Corporation (NASDAQ: DVAX) in connection with its potential sale to Sanofi. The firm is examining whether the proposed offer of $15.50 per share in cash for Dynavax shareholders represents a fair deal. Shareholders are encouraged to contact Monteverde & Associates PC for further information without cost or obligation.
Sanofi acquires Dynavax for $2.2bn, adding Hepatitis B vax and shingles candidate
Sanofi is set to acquire Dynavax for $2.2 billion to bolster its adult immunization portfolio. This acquisition will add Dynavax's marketed adult hepatitis B vaccine, HEPLISAV-B, and its phase I/II shingles vaccine candidate, Z-1018, to Sanofi's offerings. The deal aims to address significant public health challenges related to Hepatitis B and shingles, expanding Sanofi's global vaccine presence.
Evaluating Dynavax (DVAX) After Its Recent Share Price Rally: Is the Stock Still Undervalued?
Dynavax Technologies (DVAX) has seen significant share price appreciation in recent months, with the stock up 41% in one month and 52% in three months. Despite this rally, the company is still considered undervalued by analysts, with a fair value estimate of $19.25 against its current $15.38 share price. This upside relies on successful pipeline development and market share for its HEPLISAV-B vaccine, although risks like clinical trial stumbles could impact this outlook.
Dynavax Technologies Corporation $DVAX Shares Sold by Chicago Capital LLC
Chicago Capital LLC significantly reduced its stake in Dynavax Technologies Corporation (NASDAQ:DVAX) by 17.6% in the third quarter, selling over 900,000 shares. Concurrently, COO David F. Novack also sold 30,000 shares, decreasing his holding by over 21%. Despite these sales, Dynavax posted better-than-expected quarterly results with EPS of $0.21 and revenue of $94.88 million, while analysts maintain an average "Hold" rating with a consensus price target of $24.33.
Sanofi adds HBV vaccine, shingles candidate via Dynavax takeout: Deals Report
Sanofi acquired Dynavax for $2.2 billion, gaining a marketed hepatitis B vaccine and a clinical-stage shingles candidate, marking its third billion-dollar acquisition in 2025. The deal involved Sanofi paying $15.50 per share for Dynavax Technologies Corp.
Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies Corporation - DVAX
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Dynavax Technologies Corporation (DVAX) to Sanofi (SNY) for $15.50 per share. KSF is scrutinizing whether this offering adequately values Dynavax and if the process leading to the transaction was appropriate. Shareholders concerned about the valuation or their legal rights are encouraged to contact KSF.
CORRECTING and REPLACING Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies Corporation - DVAX
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Dynavax Technologies Corporation (NasdaqGS: DVAX) to Sanofi (NYSE: SNY) for $15.50 per share in cash. KSF is scrutinizing whether this offering price and the process leading to the transaction adequately value Dynavax and its shareholders. Shareholders who believe the offer undervalues the Company are encouraged to contact KSF to discuss their legal options.
Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies Corporation - DVAX
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Dynavax Technologies Corporation (NasdaqGS: DVAX) to Sanofi (NYSE: SNY) for $15.50 per share in cash. KSF is assessing whether this consideration and the process leading to it are adequate, suspecting that the offer may undervalue Dynavax. Shareholders who believe the transaction undervalues the company are encouraged to contact KSF to discuss their legal rights, especially given the tender offer structure.
Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies Corporation - DVAX
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Dynavax Technologies Corporation (NasdaqGS: DVAX) to Sanofi, questioning the adequacy of the $221.50 per share cash consideration for Cidara shareholders and the process leading to the transaction. KSF is urging shareholders who believe the offer undervalues the company to contact them to discuss their legal rights. The firm emphasizes the time-sensitive nature of the tender offer structure.
Sanofi agrees to acquire DynaVax for $2.2 bln, adds hepatitis B vaccine
Sanofi has agreed to acquire Dynavax Technologies for approximately $2.2 billion, a deal expected to close in Q1 2026. This acquisition will add Dynavax's adult hepatitis B vaccine, HEPLISAV-B®, and a shingles vaccine candidate, Z-1018, to Sanofi's portfolio. The transaction enhances Sanofi's vaccine offerings with a currently marketed product and a promising pipeline candidate.
Dynavax Technologies Signs Agreement and Plan of Merger With Sanofi
Dynavax Technologies has entered into an Agreement and Plan of Merger with Sanofi, under which Sanofi will acquire Dynavax. Sanofi plans to launch a cash tender offer of $15.50 per share for all Dynavax shares, followed by a merger that will make Dynavax a wholly-owned subsidiary. The transaction aims to provide immediate cash value to shareholders and integrate Dynavax into Sanofi's global platform.
Sanofi (SNY) to Acquire Dynavax Technologies Corporation (DVAX)
Sanofi (NASDAQ: SNY) announced a definitive agreement to acquire Dynavax Technologies Corporation (NASDAQ: DVAX) for $15.50 per share in cash, valuing the deal at approximately $2.2 billion in equity. This acquisition aims to expand Sanofi's adult immunization presence, specifically leveraging Dynavax's marketed hepatitis B vaccine, HEPLISAV-B, and a shingles vaccine candidate. The deal, unanimously approved by Dynavax's board, is expected to close in Q1 2026 and will not impact Sanofi's 2025 financial guidance.
Sanofi (SNY) to Acquire Dynavax Technologies Corporation (DVAX)
Sanofi (SNY) announced its definitive agreement to acquire Dynavax Technologies Corporation (DVAX) for approximately $2.2 billion in equity value ($15.50 per share in cash). The acquisition will expand Sanofi's adult immunization portfolio with Dynavax's hepatitis B vaccine, HEPLISAV-B, and a shingles vaccine candidate. The deal, which has been unanimously approved by Dynavax's board, is expected to close in Q1 2026 and will not impact Sanofi's 2025 financial guidance.
Exchange Traded Concepts LLC Has $2 Million Stake in Dynavax Technologies Corporation $DVAX
Exchange Traded Concepts LLC significantly increased its stake in Dynavax Technologies Corporation by 50.4% in Q3, bringing its holdings to 200,976 shares valued at approximately $1.996 million. The biopharmaceutical company recently beat earnings estimates with $0.21 EPS on $94.88 million revenue, though it maintains a negative net margin and P/E ratio. Institutional ownership remains high at 96.96%, with analysts giving the stock a "Hold" consensus rating and a $24.33 price target.
The Dynavax Turnaround: From Clinical Setbacks to a $2.2 Billion Exit
Dynavax Technologies Corporation (NASDAQ: DVAX) has been acquired by Sanofi (NASDAQ: SNY) for $2.2 billion, marking a significant turnaround for the biotech company. Once plagued by clinical setbacks, Dynavax pivoted its focus to become a leader in adult vaccines, primarily driven by its HEPLISAV-B Hepatitis B vaccine and CpG 1018 adjuvant. This acquisition validates Dynavax's strategic shift and successful commercialization efforts, providing Sanofi with a strong foothold in the growing adult immunization market.
Dynavax (DVAX) Rockets 38% on Sanofi $2-Billion Merger
Dynavax Technologies Corp. (NASDAQ:DVAX) rallied 38.19% after announcing an agreement to be acquired by Sanofi for $2.2 billion. Sanofi will purchase all outstanding shares at $15.50 apiece to enhance its adult immunization portfolio, specifically with Dynavax's Heplisav-B hepatitis B vaccine and its shingles vaccine candidate. Dynavax CEO Ryan Spencer stated that joining Sanofi will provide the global scale and expertise to maximize its vaccine portfolio's impact.
Sanofi pushes ahead on adult vaccines with $2.2 billion Dynavax deal
Sanofi announced its agreement to acquire U.S. biotech Dynavax Technologies for approximately $2.2 billion, adding an adult hepatitis B vaccine and a promising experimental shingles shot to its portfolio. This acquisition aims to diversify Sanofi's vaccine business, especially given new U.S. policy changes affecting childhood immunizations. The deal, expected to close in Q1 2026, will also bring Dynavax's Heplisav-B and an experimental shingles vaccine, Z-1018, into Sanofi's product pipeline to drive future revenue growth.
Sanofi’s Vaccine Lineup Gets a Shot in the Arm With $2.2B Dynavax Acquisition
Sanofi is acquiring Dynavax Technologies for $2.2 billion to bolster its vaccine portfolio, gaining a commercialized hepatitis B vaccine and a clinical-stage shingles vaccine. The acquisition aims to provide Sanofi with competitive advantages over rival GSK, particularly with Dynavax's two-injection hepatitis B vaccine compared to GSK's three-shot regimen and Dynavax's shingles vaccine candidate that showed fewer side effects than Shingrix. This marks Sanofi's second billion-dollar vaccine acquisition of 2025.
Dynavax Technologies Stock Soars on Buyout Buzz
Dynavax Technologies Corp (NASDAQ:DVAX) stock has surged by nearly 39% following reports that Sanofi (SNY) plans to acquire the company in an all-cash deal valued at approximately $2.2 billion, expected to close in Q1 2026. This news has DVAX trading at three-year highs and up over 20% year-to-date, with significant short covering potentially amplifying the gains. The stock's short interest represents a substantial 12.3% of its available float.
Shareholder Alert: The Ademi Firm investigates whether Dynavax Technologies Corporation is obtaining a Fair Price for its Public Shareholders
The Ademi Firm is investigating Dynavax Technologies Corporation (Nasdaq: DVAX) following its announced transaction with Sanofi, which values Dynavax at $2.2 billion, or $15.50 per share in cash. The investigation focuses on potential breaches of fiduciary duty by Dynavax's board of directors, particularly concerning the fairness of the price for public shareholders and the implications of change of control arrangements for insiders. The firm is also examining whether the transaction agreement unreasonably limits competing bids.
Why Dynavax Stock Soared Today
Dynavax Technologies stock surged over 38% after Sanofi announced an all-cash tender offer to acquire the vaccine maker. Sanofi's bid of $15.50 per share values Dynavax at approximately $2.2 billion, representing a 39% premium. The acquisition is expected to close in the first quarter of 2026, combining Dynavax's hepatitis B and shingles vaccine candidates with Sanofi's global capabilities.
Dynavax Stock Climbs: Is It Time to Ride the Wave?
Dynavax Technologies Corporation's stock (NASDAQ: DVAX) has climbed by 38.68% due to increased investor enthusiasm, fueled by positive clinical trial results for a new vaccine, new government contracts, and potential international collaborations. The biotech company shows strong financial health with high gross margins and operational cash flow, despite negative profit margins and return on equity. Market anticipation is high for potential FDA approval of its latest research findings, suggesting continued growth for Dynavax.
Shareholder Alert: The Ademi Firm investigates whether Dynavax Technologies Corporation is obtaining a Fair Price for its Public Shareholders
The Ademi Firm is investigating Dynavax Technologies Corporation (Nasdaq: DVAX) for potential breaches of fiduciary duty regarding its transaction with Sanofi, where shareholders are set to receive $15.50 per share. The firm is concerned that the $2.2 billion valuation may not be fair, especially given the provisions that limit competing offers and potential benefits to insiders. Shareholders are encouraged to contact Ademi LLP for more information about the investigation.
Shareholder Alert: The Ademi Firm investigates whether Dynavax Technologies Corporation is obtaining a Fair Price for its Public Shareholders
The Ademi Firm is investigating Dynavax Technologies Corporation (Nasdaq: DVAX) regarding its recently announced transaction with Sanofi, questioning if the $15.50 per share cash offer, valuing Dynavax at $2.2 billion, represents a fair price for public shareholders. Concerns include substantial benefits for insiders through change of control arrangements and a significant penalty for accepting competing bids, leading to an investigation into the Dynavax board's fiduciary duties.
Shareholder Alert: The Ademi Firm investigates whether Dynavax Technologies Corporation is obtaining a Fair Price for its Public Shareholders
The Ademi Firm is investigating Dynavax Technologies Corporation (Nasdaq: DVAX) for potential breaches of fiduciary duty related to its proposed transaction with Sanofi. The investigation aims to determine if the $15.50 per share cash offer, valuing Dynavax at $2.2 billion, is fair to public shareholders, especially given that insiders are receiving substantial benefits and the agreement includes a significant penalty for competing bids. Shareholders are encouraged to contact the firm for more information regarding the investigation.
